Aldosterone, mineralocorticoid receptor, and heart failure

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Nephrology

Background:

• Mineralocorticoid receptor (MR) antagonists show significant benefits in heart failure, myocardial infarction, hypertension, and diabetic nephropathy.
• Aldosterone's role extends beyond hydro-mineral balance, influencing blood pressure and causing detrimental structural and functional changes in cardiovascular tissues.
• Chronic MR activation, independent of salt balance, leads to cardiac and renal fibrosis, inflammation, and vascular remodeling.

Purpose of the Study:

• To re-evaluate the traditional view of aldosterone's action, focusing on its broader effects beyond sodium reabsorption.
• To investigate the deleterious cardiovascular effects of chronic mineralocorticoid receptor activation.
• To emphasize the importance of mineralocorticoid receptor inhibition in cardiovascular health.

Main Methods:

• Analysis of large clinical studies on MR antagonists.
• Review of experimental studies in diverse animal models, including transgenic mice.
• Examination of the interplay between aldosterone, glucocorticoids, and MR activation in cardiovascular tissues.

Main Results:

• Clinical studies confirm the benefits of MR antagonists in various cardiovascular conditions.
• Experimental data reveal that chronic MR overactivation induces fibrosis, inflammation, and remodeling in the heart, kidneys, and vasculature.
• The role of aldosterone as the primary MR ligand is debated, with glucocorticoids also implicated, particularly in the heart.

Conclusions:

• Elevated mineralocorticoid receptor activation, even when not driven by salt imbalance, has detrimental cardiovascular consequences.
• MR inhibition is crucial for managing conditions associated with excessive MR signaling.
• Understanding the complex ligand-receptor interactions is vital for cardiovascular protection.